SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Andreasen Anne H.) srt2:(2015-2019)"

Sökning: WFRF:(Andreasen Anne H.) > (2015-2019)

  • Resultat 1-3 av 3
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Petrov, Dmitry, et al. (författare)
  • Machine Learning for Large-Scale Quality Control of 3D Shape Models in Neuroimaging
  • 2017
  • Ingår i: Machine learning in medical imaging. MLMI (Workshop). ; 10541, s. 371-378
  • Tidskriftsartikel (refereegranskat)abstract
    • As very large studies of complex neuroimaging phenotypes become more common, human quality assessment of MRI-derived data remains one of the last major bottlenecks. Few attempts have so far been made to address this issue with machine learning. In this work, we optimize predictive models of quality for meshes representing deep brain structure shapes. We use standard vertex-wise and global shape features computed homologously across 19 cohorts and over 7500 human-rated subjects, training kernelized Support Vector Machine and Gradient Boosted Decision Trees classifiers to detect meshes of failing quality. Our models generalize across datasets and diseases, reducing human workload by 30-70%, or equivalently hundreds of human rater hours for datasets of comparable size, with recall rates approaching inter-rater reliability.
  •  
2.
  •  
3.
  • Landen, Jaren W., et al. (författare)
  • Ponezumab in mild-to-moderate Alzheimer's disease : Randomized phase II PET-PIB study
  • 2017
  • Ingår i: Alzheimer's and Dementia: Translational Research and Clinical Interventions. - : John Wiley and Sons. ; 3:3, s. 393-401
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti-Aβ monoclonal antibody, were characterized in subjects with mild-to-moderate Alzheimer's disease treated for 1 year. Methods Subjects were aged ≥50 years with Mini–Mental State Examination scores 16 to 26. Cohort Q was randomized to ponezumab 10 mg/kg (n = 12) or placebo (n = 6) quarterly. Cohort M was randomized to a loading dose of ponezumab 10 mg/kg or placebo, followed by monthly ponezumab 7.5 mg/kg (n = 12) or placebo (n = 6), respectively. Results Ponezumab was generally well tolerated. Plasma concentrations increased dose dependently, but cerebrospinal fluid (CSF) penetration was low. Plasma Aβ increased dose dependently with ponezumab, but CSF biomarkers, brain amyloid burden, cognition, and function were not affected. Conclusions Both ponezumab dosing schedules were generally safe and well tolerated but did not alter CSF biomarkers, brain amyloid burden, or clinical outcomes.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-3 av 3

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy